Patents Examined by Brian Whiteman
  • Patent number: 11597935
    Abstract: Embodiments of the disclosure include compositions and methods for generating RNA nanostructures, particularly in a cell. In particular embodiments, RNA subunits comprising at least one three-way junction and at least one kissing loop are configured such that multiple RNA subunits can polymerize into a specific structure. In particular embodiments, the RNA subunits are configured such that sequence of at least one kissing loop is complementary to sequence of another kissing loop, such as on another RNA subunit, and the summation of multiple RNA subunits having specific individual structures results in a combined polymerized structure of a defined shape. In specific embodiments, an RNA nanostructure generated from methods herein is utilized for an application, such as manufacturing or genetic modifications in a cell.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: March 7, 2023
    Assignee: Baylor College of Medicine
    Inventor: Laising Yen
  • Patent number: 11591603
    Abstract: The invention relates to a nucleic acid aptamer with the capability of binding specifically to a and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TLR-4.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: February 28, 2023
    Assignee: APTATARGETS, S.L.
    Inventors: Ignacio Lizasoain Hernandez, Victor Manuel Gonzalez Muñoz, Geronimo Fernandez Gomez-Chacon, Maria Angeles Moro Sanchez, Maria Elena Martin Palma, Ana Moraga Yebenes
  • Patent number: 11591597
    Abstract: The present invention includes methods for detecting and reducing or inhibiting ischemic stroke in a mammal, the method comprising: (a) selecting microRNAs to downregulate selected from the group consisting of hsa-miR-96-5p, hsa-miR-99a-5p, hsa-miR-122-5p, hsa-miR-186-5p, hsa-miR-211-5p, hsa-mir-760, PC-3p-57664, or PC-5p-12969, (b) selecting microRNAs to upregulate selected from the group consisting of ggo-miR-139, hsa-miR-30d-5p, hsa-miR-22-3p, hsa-miR-23a-3p, mmu-miR-5124a, mmu-mir-6240-5p, PC-3p-32463, or PC-5p-211, and combinations thereof, and (c) administering an agent that: downregulates that targets in (a), upregulates the targets in (b), or both, to the subject in an amount sufficient to reduce or inhibit ischemic stroke in the mammal. The present invention also includes the detection of the markers for use with stroke patients.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: February 28, 2023
    Assignee: Texas Tech University System
    Inventors: P. Hemachandra Reddy, Murali Vijayan
  • Patent number: 11584935
    Abstract: The present disclosure provides materials and methods for the delivery of therapeutic nucleic cells (and imaging agents) to tissues.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: February 21, 2023
    Inventors: Paolo Serafini, Dimitri Van Simaeys, Adriana De La Fuente, Alessia Zoso, Silvio Bicciato, Jimmy Caroli, Cristian Taccioli, Andrea Grilli, Midhat Abdulreda
  • Patent number: 11584933
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: February 21, 2023
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • Patent number: 11576976
    Abstract: The present invention is related to a method for treating cancer by using siRNA nanocomplex consisting of a nucleic acid molecule, a monocationic drug and a biocompatible polymer surfactant. The present nanocomplex can deliver an active ingredient (for example, a nucleic acid molecule and monocationic drug) into a cell/tissue of interest in a stable manner, and may be effectively applied for treating or detecting diverse disorders (practically, cancers).
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 14, 2023
    Assignee: D. R. NANO CO., LTD.
    Inventors: Sehoon Kim, Ick Chan Kwon, Eunjung Lee
  • Patent number: 11572562
    Abstract: This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes. Disclosed oligonucleotides for the reduction of GYS2 expression may be double-stranded or single-stranded, and may be modified for improved characteristics such as stronger resistance to nucleases and lower immunogenicity. Disclosed oligonucleotides for the reduction of GYS2 expression may also include targeting ligands to target a particular cell or organ, such as the hepatocytes of the liver, and may be used to treat glycogen storage diseases (e.g., GSDIa, GSDIII, GSDIV, GSDVI, and GSDIX) and related conditions.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: February 7, 2023
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Natalie Pursell, Henryk T. Dudek, Cheng Lai
  • Patent number: 11566262
    Abstract: The invention provides inducible promoter systems and their components incorporating components of a tetracycline operon. By coordinating expression of different transcriptional units in these systems as a result of selection of promoters and/or linking the units into the same DNA molecule, these systems can achieve higher levels of expression of coding segments of interest, increased differential levels of expression between on- and off-states, and/or greater responsiveness to inducing agents than conventional systems.
    Type: Grant
    Filed: March 21, 2022
    Date of Patent: January 31, 2023
    Assignee: DNA TWOPOINTO INC.
    Inventor: Jeremy Minshull
  • Patent number: 11560566
    Abstract: Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity and/or improving the specificity of RNA-programmable proteins, such as Cas9. For example, provided are guide RNAs (gRNAs) that are engineered to exist in an “on” or “off” state, which control the binding and, in certain instances, cleavage activity of RNA-programmable proteins (e.g., RNA-programmable endonucleases). By incorporating ligand-responsive self-cleaving catalytic RNAs (aptazymes) into guide RNAs, a set of aptazyme-embedded guide RNAs was developed that enable small molecule-controlled nuclease-mediated genome editing and small molecule-controlled base editing, as well as small molecule-dependent transcriptional activation in mammalian cells.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: January 24, 2023
    Assignee: President and Fellows of Harvard College
    Inventors: Weixin Tang, Johnny Hao Hu, David R. Liu
  • Patent number: 11555191
    Abstract: An inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus is provided.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: January 17, 2023
    Inventors: Jean Pierre Quivy, Barbara Testoni, Fabien Zoulim, Maelle Locatelli
  • Patent number: 11549107
    Abstract: Compositions and methods for introducing double-stranded breaks within the SERPINA1 gene are provided. Compositions and methods for reducing and eliminating mutant forms of ?1-antitrypsin (AAT), such as seen in subjects having ?1-antitrypsin deficiency (AATD), are provided.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: January 10, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Shobu Odate, Walter Strapps, Reynald Michael Lescarbeau
  • Patent number: 11549112
    Abstract: The present disclosure relates to RNAi agents, e.g., double stranded RNAi agents, able to inhibit xanthine dehydrogenase (XDH) gene expression. Also disclosed are pharmaceutical compositions that include XDH RNAi agents and methods of use thereof. The XDH RNAi agents disclosed herein may be conjugated to targeting ligands to facilitate the delivery to cells, including to hepatocytes. Delivery of the XDH RNAi agents in vivo provides for inhibition of XDH gene expression. The RNAi agents can be used in methods of treatment of diseases, disorders, or symptoms mediated in part by XDH gene expression, such as gout and hyperuricemia.
    Type: Grant
    Filed: May 19, 2022
    Date of Patent: January 10, 2023
    Inventors: Anthony Nicholas, Tao Pei, Zhao Xu, Daniel Braas, Zhi-Ming Ding
  • Patent number: 11542502
    Abstract: Disclosed are methods of using a microRNA-210 inhibitor in preparation of drugs for treating inflammatory skin diseases. The present inventor has demonstrated through a large number of experiments that in vitro inhibition of microRNA-210 expression can significantly enhance the expression of its target gene STAT6, thereby inhibiting proliferation and chemokine CCL20 secretion of keratinocytes, further inhibiting chemotactic T cell migration towards skin lesion, and also inhibiting differentiation of TH1 and TH17. MicroRNA-210 knockout and intradermal injection of a microRNA-210 inhibitor (cholesterol-modified antagomiR-210) on a skin lesion specifically inhibit the expression of microRNA-210, so that skin inflammation in mice can be significantly inhibited, and T cell immune imbalance is mitigated. The present invention provides a new pathophysiological mechanism for inflammatory skin diseases and provides a new strategy for preparing drugs for treating inflammatory skin diseases.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: January 3, 2023
    Inventors: Qianjin Lu, Ming Zhao, Yuwen Su, Ruifang Wu
  • Patent number: 11534452
    Abstract: A method for identifying a compound that prevents, ameliorates and/or inhibits a hepatitis B virus (HBV) infection is provided, wherein a compound that reduces the expression and/or activity of PAP associated domain containing 5 (PAPD5) and/or PAP associated domain containing 7 (PAPD7) is identified as a compound that prevents, ameliorates and/or inhibits a HBV infection. Inhibitors of PAPD5 or PAPD7 are provided for use in treating and/or preventing a HBV infection; as well as a combined preparation comprising an inhibitor of PAPD5 and an inhibitor of PAPD7 for simultaneous or sequential use in the treatment or prevention of a HBV infection.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: December 27, 2022
    Inventors: Hassan Javanbakht, Søren Ottosen, Lykke Pedersen, Henrik Mueller
  • Patent number: 11535849
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
    Type: Grant
    Filed: June 1, 2020
    Date of Patent: December 27, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Brett P. Monia, Susan M. Freier, Andrew M. Siwkowski, Shuling Guo
  • Patent number: 11529428
    Abstract: The present invention provides methods comprising the in vivo delivery of small nucleic acid molecules capable of mediating RNA interference and reducing the expression of myostatin, wherein the small nucleic acid molecules are introduced to a subject by systemic administration. Specifically, the invention relates to methods comprising the in vivo delivery of short interfering nucleic acid (siNA) molecules that target a myostatin gene expressed by a subject, wherein the siNA molecule is conjugated to a lipophilic moiety, such as cholesterol. The myostatin siNA conjugates that are delivered as per the methods disclosed are useful to modulate the in vivo expression of myostatin, increase muscle mass and/or enhance muscle performance. Use of the disclosed methods is further indicated for treating musculoskeletal diseases or disorders and/or diseases or disorders that result in conditions in which muscle is adversely affected.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: December 20, 2022
    Inventors: Marija Tadin-Strapps, Tayeba Khan, Walter Richard Strapps, Laura Sepp-Lorenzino, Vasant R. Jadhav, Duncan Brown
  • Patent number: 11518991
    Abstract: A method for re-expression of hypermethylated RASAL1, hypermethylated LRFN2, and hypermethylated KLOTHO based on an inactivated CRISPR-based system and a DNA dioxygenase as well as a gRNA guiding the construct to the RASAL1, LRFN2, and KLOTHO gene for demethylation of hypermethylated RASAL1, hypermethylated LRFN2, and hypermethylated KLOTHO, in particular, hypermethylated RASAL1, LRFN2, and KLOTHO promoter, thus, allowing re-expression of RASAL1, LRFN2, and KLOTHO for the treatment of fibrosis, cancer or neuronal disorders in a subject is provided. A kit of parts for allowing re-expression of hypermethylated RASAL1, hypermethylated LRFN2, and hypermethylated KLOTHO in a subject, a vector or vector system, and nucleic acid constructs are also provided.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: December 6, 2022
    Assignee: Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin
    Inventors: Elisabeth Zeisberg, Xingbo Xu
  • Patent number: 11512309
    Abstract: The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.
    Type: Grant
    Filed: May 12, 2021
    Date of Patent: November 29, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Kavita Praveen, Claudia Schurmann, Lauren Gurski, Tanya Teslovich Dostal, Goncalo Abecasis, Aris Baras, Giovanni Coppola
  • Patent number: 11510997
    Abstract: Polynucleotides encoding peptides, proteins, enzymes, and functional fragments thereof are disclosed. The polynucleotides of the disclosure can be effectively delivered to an organ, such as the lung, and expressed within cells of the organ. The polyribonucleotides of the disclosure can be used to treat a disease or condition associated with cilia maintenance and function, impaired function of the axoneme, such as DNAI1 or DNAH5.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: November 29, 2022
    Assignee: TranscripTx, Inc.
    Inventors: David J. Lockhart, Brandon Wustman, Mirko Hennig, Daniella Ishimaru
  • Patent number: 11505807
    Abstract: In one aspect, the invention relates to a method of loading exosomes with oligonucleotide cargo, by incubating an oligonucleotide comprising one or more hydrophobic modifications with a population of exosomes for a period of time sufficient to allow loading of the exosomes with the oligonucleotide. Exosomes loaded with hydrophobically modified oligonucleotide cargo, and uses thereof, are also provided.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: November 22, 2022
    Assignee: University of Massachusetts
    Inventors: Anastasia Khvorova, Neil Aronin, Marie Cecile Didiot, Reka Haraszti